Core Viewpoint - The Hong Kong Special Administrative Region (HKSAR) government has officially launched the "Guangdong-Hong Kong-Macao Greater Bay Area Clinical Trial Collaboration Platform," aimed at integrating clinical trial resources in the Greater Bay Area to provide a one-stop service for global biopharmaceutical companies and researchers focusing on advanced therapies such as rare disease drugs, high-end oncology drugs, and cell and gene therapies [1][2] Group 1 - The "Guangdong-Hong Kong-Macao Greater Bay Area Clinical Trial Collaboration Platform" is established as a unified service portal to enhance clinical trial resources [1] - The platform will support the registration applications of innovative drugs and medical devices in Hong Kong, mainland China, and overseas by utilizing real-world data generated under the "Hong Kong-Macao Drug and Device Access" policy [1] - As of December 10, 2023, 71 designated mainland medical institutions have introduced 140 types of drugs and medical devices that are already listed in Hong Kong and Macao, benefiting over 17,000 patients [1] Group 2 - The clinical trial institution aims to leverage the complete biopharmaceutical technology R&D and industrial chain in the Greater Bay Area, utilizing special policies that benefit Hong Kong [2] - The initiative is expected to accelerate patient access to advanced treatments in the Greater Bay Area and develop new productive forces [2]